Patient characteristics
| Patient characteristics . | Primary donor (n = 25) . | Third party (n = 76) . | Both (n = 3) . | All (N = 104) . |
|---|---|---|---|---|
| Age, median (range), y | 55.9 (0.6-73.0) | 49.9 (0.3-69.7) | 62.0 (13.4-67.4) | 51.8 (0.3-73.0) |
| Sex, male/female, n | 12/13 | 40/36 | 1/2 | 53/51 |
| Malignant/nonmalignant, n | 21/4 | 64/12 | 2/1 | 87/17 |
| Stem cell source, n | ||||
| Conventional BM | 1 | 5 | 1 | 7 |
| Conventional PBSC | 1 | 12 | 0 | 13 |
| Unrelated cord | 0 | 9 | 0 | 9 |
| CD34-selected TCD PBSC | 22 | 48 | 2 | 72 |
| CD34-selected TCD BM | 1 | 1 | 0 | 2 |
| PT Cy TCD | 0 | 1 | 0 | 1 |
| CMV serostatus, n | ||||
| D+/R+ | 24 | 29 | 3 | 56 |
| D−/R+ | 0 | 38 | 0 | 38 |
| Unknown | 1 | 9 | 0 | 10 |
| HLA matching, n | ||||
| Matched | 19 | 32 | 3 | 54 |
| Mismatched | 6 | 44 | 0 | 50 |
| HCT to CMV reactivation (range), d | 28 (4-2520) | 27 (38-4655) | 24 (19-82) | 28 (38-4655) |
| HCT to first CTLs (range), d | 116 (76-2763) | 132 (29-4940) | 128 (59-385) | 128 (29-4940) |
| Immunosuppression at first CTLs, n | 4 | 36 | 1 | 41 |
| Number of cycles, n | ||||
| 1 | 21 | 40 | 0 | 61 |
| 2 | 2 | 22 | 0 | 24 |
| 3 | 1 | 6 | 3 | 10 |
| ≥4 | 1 | 8 | 0 | 9 |
| Response, n | ||||
| Responder (CR/PR) | 17 | 40 | 3 | 60 |
| Nonresponder (SD/POD) | 4 | 21 | 0 | 25 |
| Not evaluable | 4 | 15 | 0 | 19 |
| Death from CMV, n | 7 | 12 | 1 | 20 |
| Patient characteristics . | Primary donor (n = 25) . | Third party (n = 76) . | Both (n = 3) . | All (N = 104) . |
|---|---|---|---|---|
| Age, median (range), y | 55.9 (0.6-73.0) | 49.9 (0.3-69.7) | 62.0 (13.4-67.4) | 51.8 (0.3-73.0) |
| Sex, male/female, n | 12/13 | 40/36 | 1/2 | 53/51 |
| Malignant/nonmalignant, n | 21/4 | 64/12 | 2/1 | 87/17 |
| Stem cell source, n | ||||
| Conventional BM | 1 | 5 | 1 | 7 |
| Conventional PBSC | 1 | 12 | 0 | 13 |
| Unrelated cord | 0 | 9 | 0 | 9 |
| CD34-selected TCD PBSC | 22 | 48 | 2 | 72 |
| CD34-selected TCD BM | 1 | 1 | 0 | 2 |
| PT Cy TCD | 0 | 1 | 0 | 1 |
| CMV serostatus, n | ||||
| D+/R+ | 24 | 29 | 3 | 56 |
| D−/R+ | 0 | 38 | 0 | 38 |
| Unknown | 1 | 9 | 0 | 10 |
| HLA matching, n | ||||
| Matched | 19 | 32 | 3 | 54 |
| Mismatched | 6 | 44 | 0 | 50 |
| HCT to CMV reactivation (range), d | 28 (4-2520) | 27 (38-4655) | 24 (19-82) | 28 (38-4655) |
| HCT to first CTLs (range), d | 116 (76-2763) | 132 (29-4940) | 128 (59-385) | 128 (29-4940) |
| Immunosuppression at first CTLs, n | 4 | 36 | 1 | 41 |
| Number of cycles, n | ||||
| 1 | 21 | 40 | 0 | 61 |
| 2 | 2 | 22 | 0 | 24 |
| 3 | 1 | 6 | 3 | 10 |
| ≥4 | 1 | 8 | 0 | 9 |
| Response, n | ||||
| Responder (CR/PR) | 17 | 40 | 3 | 60 |
| Nonresponder (SD/POD) | 4 | 21 | 0 | 25 |
| Not evaluable | 4 | 15 | 0 | 19 |
| Death from CMV, n | 7 | 12 | 1 | 20 |
BM, bone marrow; D+, donor positive; D−, donor negative; PBSC, peripheral blood stem cell; PT Cy, posttransplant cyclophosphamide; R+, recipient positive; TCD, T-cell depleted.